Saakshi Medtech & Panels Ltd

As of November 6, 2025, Saakshi Medtech is considered very expensive and overvalued with a PE ratio of 65.09, an EV to EBITDA ratio of 31.15, and a year-to-date return of -22.64%, significantly underperforming compared to its peers and the Sensex.

As of 24-Oct, Saakshi Medtech & Panels Ltd's stock price is declining at 153.40, down 1.98%, and has underperformed its sector. Despite increased investor participation, the stock has dropped 5.86% over the past week and has a year-to-date return of -30.27%, contrasting with the broader market's positive performance.

As of 17-Oct, Saakshi Medtech & Panels Ltd's stock price is declining at 162.95, down 0.49%, and has underperformed its sector. Despite trading above key moving averages and increased investor participation, the stock has shown significant losses over various periods, indicating ongoing challenges amid a generally positive market.

As of 30-Sep, Saakshi Medtech & Panels Ltd's stock price is at 172.00, down 1.99%, and has underperformed its sector. Despite increased investor participation, the stock's negative returns and lack of clear catalysts contribute to its downward trend compared to the benchmark Sensex.

As of 19-Sep, Saakshi Medtech & Panels Ltd's stock price is at 184.00, down 4.09%, despite trading above key moving averages. The stock has underperformed the Sensex year-to-date, with a decline of 16.36%, although there is increased investor interest indicated by a 140% rise in delivery volume.

As of 16-Sep, Saakshi Medtech & Panels Ltd is priced at 191.85, having recently gained +11.06% over the past week, but it has a year-to-date return of -12.80%, indicating long-term challenges despite recent short-term gains. The stock is trading above all key moving averages and has seen a 140% increase in delivery volume.

As of 15-Sep, Saakshi Medtech & Panels Ltd is currently priced at 191.90, reflecting a recent increase of 4.86% and strong performance relative to its sector. Despite a decline in investor participation, the stock has gained 16.62% over the past week, indicating a potential recovery phase.

As of 12-Sep, Saakshi Medtech & Panels Ltd's stock price is at 183.00, down 3.17%, and has underperformed its sector today. Despite recent positive returns over the week and month, it has significantly declined by 28.28% over the past year, indicating ongoing challenges affecting investor confidence.

As of 11-Sep, Saakshi Medtech & Panels Ltd is currently priced at 189.00, up 4.22%, and has outperformed its sector today. However, it has underperformed against the benchmark over the past year, with a 22.22% decline, and its year-to-date performance shows a 14.09% drop compared to the Sensex's gain.

As of 08-Sep, Saakshi Medtech & Panels Ltd is priced at 164.55, showing a bearish trend with a year-to-date decline of 25.20%. Despite a recent increase in investor participation, the stock is underperforming compared to the broader market, which has gained 4.77% year-to-date.

As of 05-Sep, Saakshi Medtech & Panels Ltd's stock price is declining at 164.30, down 2.78%, and has underperformed its sector by 3.48%. The stock has seen a significant drop in investor participation and has a year-to-date decline of 25.32%, contrasting sharply with the Sensex's 4.64% gain.

As of 26-Aug, Saakshi Medtech & Panels Ltd's stock price is at 186.75, down 2.71%, with a year-to-date decline of 15.11%. Despite a recent short-term increase of 1.63%, its longer-term performance remains weak compared to the Sensex.

As of 25-Aug, Saakshi Medtech & Panels Ltd is priced at 191.95, showing no change. The stock has recently increased by 9.06% over the past week, outperforming the Sensex, but has significant year-to-date and one-year declines of 12.75% and 21.65%, respectively, indicating mixed performance trends.

As of August 22, 2025, Saakshi Medtech is considered overvalued with a high PE ratio of 72.10 and a year-to-date return of -12.75%, indicating it is priced above its fundamental value compared to peers like Tata Chemicals.

As of August 22, 2025, Saakshi Medtech is considered overvalued with a PE ratio of 72.10 and lower return metrics compared to peers, despite a recent stock return of 8.29%.

As of August 22, 2025, Saakshi Medtech is considered overvalued with a PE ratio of 72.10 and an EV to EBITDA ratio of 33.18, despite a slight improvement in valuation grade, as it has underperformed with a -23.71% return compared to the Sensex's 0.24% gain.

As of 22-Aug, Saakshi Medtech & Panels Ltd's stock price is at 191.95, down 0.44%, despite a recent 1-week return of 8.29%. The stock's year-to-date performance is -12.75%, and a significant drop in delivery volume indicates reduced investor participation, contributing to the current price decline.

As of 21-Aug, Saakshi Medtech & Panels Ltd's stock price is at 192.80, reflecting a slight decline despite an 8.77% increase over the past week. The stock has underperformed year-to-date with a 12.36% decline compared to the Sensex's gain, indicating volatility and challenges in sustaining upward momentum.

As of August 20, 2025, Saakshi Medtech is considered very expensive and overvalued with a PE ratio of 72.31, significantly higher than its peers, and has underperformed with a year-to-date return of -12.32% compared to the Sensex's gain of 5.95%.